842136-59-8

Basic information

• Product Name: N-Methoxy-N-Methyl 5-broMo-2-chlorobenzaMide
• Synonyms: N-Methoxy-N-Methyl 5-broMo-2-chlorobenzaMide
• CAS NO: 842136-59-8
• Molecular Formula: C₉H₉BrClNO₂
• Molecular Weight: 278.53026
• Mol File: 842136-59-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-Methoxy-N-Methyl 5-broMo-2-chlorobenzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methoxy-N-Methyl 5-broMo-2-chlorobenzaMide(842136-59-8)
• EPA Substance Registry System: N-Methoxy-N-Methyl 5-broMo-2-chlorobenzaMide(842136-59-8)

Safety Data

• Hazardous Substances Data: 842136-59-8(Hazardous Substances Data)

Upstream product

• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 16645-06-0 N,N-dimethylhydroxylamine hydrochloride 

Downstream Products

• 189628-37-3 2-chloro-5-bromobenzaldehyde 
• 842136-60-1 (5-bromo-2-chlorophenyl)(6-bromopyridin-3-yl)methanone 
• 1358580-81-0 (2S,3R,4S,5S,6R)-2-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)-2-methoxy-tetrahydropyran-3,4,5-triol 
• 1358580-84-3 (2S,3R,4S,5S,6R)-6-[(tert-butyl(dimethyl)silyl)oxymethyl]-2-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-2-methoxy-tetrahydropyran-3,4,5-triol 
• 1358580-87-6 [[(2R,3R,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-methoxy-tetrahydropyran-2-yl]methoxy]tert-butyl-dimethyl-silane 
• 1358580-89-8 [(2R,3R,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-methoxy-tetrahydropyran-2-yl]methanol 
• 1358580-91-2 (2S,3S,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-6-methoxy-tetrahydropyran-2-carbaldehyde 
• 1358580-93-4 (2S,3S,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-2-carbaldehyde 
• 1358580-96-7 [(3S,4S,5R,6S)-3,4,5-tribenzyloxy-6-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-2-(hydroxymethyl)-6-methoxy-tetrahydropyran-2-yl]methanol 
• 1358579-30-2 (1S,2S,3S,4R,5S)-5-[4-chloro-3-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo-[3.2.1]octane-2,3,4-triol 
• 1346239-96-0 (5-bromo-2-chloro-phenyl)-[4-(trifluoromethoxy)phenyl]methanone 
• 945717-56-6 4-bromo-1-chloro-2-(prop-1-en-2-yl)benzene 
• 105884-19-3 1-(2-bromo-5-chlorophenyl)ethan-1-one 

Relevant articles and documents

SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS

The present invention relates to substituted alkynylene compounds represented by compound of formula (I) pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the methods of preparation of compound of formula (I) and therapeutic uses thereof as anti-cancer agents.

Preparation method of Dapagliflozin isomer impurities I

The invention discloses a preparation method of Dapagliflozin isomer impurities I. The preparation method comprises the following steps that a, 2-chlorine-5-bromobenzoic acid is dissolved in a first solvent; an acylation reagent is added; reaction is perf

NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF

The present invention generally relates to an improved process for the preparation of dapagliflozin of Formula I or its solvates or co-crystals thereof. The present invention also encompasses the novel intermediates and their use in the preparation of dap

HEPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the fu

HEPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: [in-line-formulae]X-A1-Y-A2-Z-L-R??(I)[/in-line-formulae] which inhibit the protein(s) encoded by hepatitis

C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed.

Novel SGLT inhibitors

Novel compounds of formula (A) or a pharmaceutically acceptable salt thereof: wherein symbols are as defined in claims, which are useful as SGLT inhibitors and for treatment of diabetes and related diseases.

1-THIO-D-GLUCITOL DERIVATIVES

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceu

C-PHENYL GLYCITOL COMPOUND

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, R3 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, Y is a C1-6 alkylene group, -O-(CH2)n- (n is an integer of 1 to 4) or a C2-6 alkenylene group, provided that when Z is NHC(= NH)NH2 or -NHCON(RB)RC, n is not 1, Z is -CONHRA, -NHC(=NH)NH2 or -NHCON(RB)RC, Formula (A) or Formula (B).